Cover Image
市場調查報告書

藥物輸送技術市場預測 ∼2020年:各投藥途徑 (口服、經肺、注射、眼、鼻子、局部、植入、粘膜等)

Drug Delivery Technology Market by Route of Administration (Oral (Solid), Pulmonary (Nebulizer), Injectable (Device), Ocular (Liquid), Nasal (Drop), Topical (Solid), Implantable (Active), Transmucosal (Oral)), End User - Forecast to 2020

出版商 MarketsandMarkets 商品編碼 344812
出版日期 內容資訊 英文 242 Pages
訂單完成後即時交付
價格
Back to Top
藥物輸送技術市場預測 ∼2020年:各投藥途徑 (口服、經肺、注射、眼、鼻子、局部、植入、粘膜等) Drug Delivery Technology Market by Route of Administration (Oral (Solid), Pulmonary (Nebulizer), Injectable (Device), Ocular (Liquid), Nasal (Drop), Topical (Solid), Implantable (Active), Transmucosal (Oral)), End User - Forecast to 2020
出版日期: 2015年11月05日 內容資訊: 英文 242 Pages
簡介

藥物輸送技術的市場預計從2015年到2020年以7.5%的年複合成長率發展、從2015年的1兆481億美元、到2020年成長到1兆5047億美元的規模。慢性疾病的發病率上升和生物製藥市場成長、革新、技術的進步等要素,促進該市場成長。

本報告提供全球藥物輸送技術的市場相關調查,市場定義和概要,投藥途徑及劑型種類與概要,對市場成長的各種影響因素及市場機會分析,各投藥途徑、劑型、終端用戶、地區的市場趨勢與市場規模的變化與預測,競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 局部的藥物輸送技術的市場
  • 各終端用戶市場
  • 固態口服藥物輸送技術的市場
  • 各給藥途徑市場
  • 地區概要

第5章 市場概要

  • 簡介
  • 市場區隔
    • 各給藥途徑
    • 各用途
    • 各地區
  • 市場動態
    • 推進因素
    • 阻礙要素
    • 市場機會
    • 課題

第6章 市場分析:各給藥途徑

  • 簡介
  • 口服給藥
    • 固態
      • 平板電腦
      • 膠囊
      • 撲粉
      • 藥丸
    • 液體
      • 溶劑
      • 糖漿
    • 半固態
      • 凝膠
      • 乳膠
      • 酏劑
  • 肺部藥物輸送
    • 計量吸入
    • 乾粉吸入
    • 噴霧器
      • 噴氣式噴霧器
      • 超音波
      • 軟霧噴霧器
  • 注射
    • 注射器
      • 傳統注射器
      • 各材料
        • 玻璃
        • 塑膠
      • 各產品
        • 可填充注射器
        • 已填充注射器
      • 各可用性
        • 可重複使用
        • 拋棄式
      • 自行注射器
      • 無針注射器
      • 自動注射器
      • 筆型注射器
      • 穿戴式注射器
      • 其他
    • 注射用製劑
      • 傳統製劑
      • 新型製劑
      • 長時間作用性製劑
  • 眼部投藥
    • 液體
      • 點眼藥劑
      • 液體噴霧
    • 半固態
      • 凝膠
      • 眼軟膏劑
    • 接眼設備
      • 藥物塗膜隱形眼鏡
      • 眼球植入
  • 鼻腔藥物輸送
    • 點鼻子劑
    • 噴霧
    • 撲粉
    • 凝膠
  • 局部的藥物輸送
    • 液體
      • 溶劑
      • 懸浮劑
    • 半固態
      • 凝膠
      • 軟膏
    • 固態
      • 塞劑
    • 經皮藥物輸送
      • 貼片
      • 凝膠
  • 植入藥物輸送
    • 積極型
    • 被動型
  • 粘膜藥物輸送
    • 口服經粘膜
      • 口含
      • 舌下
    • 其他
      • 經肛門
      • 陰道粘膜

第7章 市場分析:各終端用戶

  • 簡介
  • 醫院
  • 居家護理
  • 門診外科醫療設施、診所
  • 診斷中心
  • 其他

第8章 市場分析:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞洲
  • 其他

第9章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢
    • 新產品的認證、投入
    • 聯盟、協定、合作
    • 收購
    • 擴張

第10章 企業簡介

  • 簡介
  • BAYER AG
  • JOHNSON & JOHNSON SERVICES, INC.
  • NOVARTIS AG
  • PFIZER, INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • 3M COMPANY
  • ANTARES PHARMA, INC.
  • GLAXOSMITHKLINE PLC
  • MERCK & CO., INC.
  • SANOFI
    • 概要
    • 財務趨勢
    • 產品與服務
    • 主要策略
    • 近幾年的發展趨勢等

第11章 附錄

圖表

目錄
Product Code: MD 3871

The drug delivery technology market is expected to reach USD 1,504.7 billion by 2020 from USD 1,048.1 billion in 2015, growing at a CAGR of 7.5% from 2015 to 2020. The market is categorized on the basis of route of administration, end user, and region. The route of administration market is further segmented into oral, pulmonary, ocular, nasal, topical, injectable, implantable and transmucosal drug delivery technology. The topical drug delivery technology market segment is expected to witness the highest CAGR in the forecast period.

Factors such as rising incidences of chronic diseases, growth of the biologics market, and innovation and technological advancements, are driving the growth of the drug delivery technology market. In addition, emphasis on innovation for improving the delivery of drugs is also contributing to the growth of the market. For instance, in February 2015, Sanofi and Mankind Corporation (U.S.) collaborated to launch Afrezza (insulin human) Inhalation Powder, inhalable insulin. This launch enabled the company to strengthen its product portfolio in nasal drug delivery. Such innovations are fueling the growth of the market.

Asia is expected to be the fastest-growing region in the drug delivery technology market. High growth in this market can be attributed to the increased population, rising prevalence of chronic diseases in the emerging markets, and existence of unmet medical needs.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the drug delivery technology market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms to garner a greater market, share. Firms purchasing the report can use one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the drug delivery technology market. The report analyzes this market by route of administration, end user, and geography
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the drug delivery technology market
  • Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the drug delivery technology market
  • Market Development: Comprehensive information about lucrative markets. The report analyzes the market for various drug delivery technology market across countries
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the drug delivery technology market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. KEY DATA FROM SECONDARY SOURCES
  • 2.4. KEY DATA FROM PRIMARY SOURCES
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. DRUG DELIVERY TECHNOLOGY MARKET, BY TOPICAL DRUG DELIVERY
  • 4.2. DRUG DELIVERY TECHNOLOGY MARKET, BY END USER
  • 4.3. SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM
  • 4.4. DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION
  • 4.5. GEOGRAPHIC SNAPSHOT OF THE DRUG DELIVERY TECHNOLOGY MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
    • 5.2.2. MARKET SEGMENTATION, BY END USER
    • 5.2.3. MARKET SEGMENTATION, BY REGION
  • 5.3. MARKET DYNAMICS
  • 5.4. DRIVERS
    • 5.4.1. RISING PREVALENCE OF CHRONIC DISEASES
    • 5.4.2. GROWTH IN THE BIOLOGICS MARKET
    • 5.4.3. NEW PRODUCT LAUNCHES
    • 5.4.4. DRUG INNOVATION AND TECHNOLOGICAL ADVANCEMENTS
  • 5.5. RESTRAINTS
    • 5.5.1. RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS RELATED TO DRUGS
  • 5.6. OPPORTUNITIES
    • 5.6.1. SELF-ADMINISTRATION AND HOMECARE DRUG DELIVERY
    • 5.6.2. RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
      • 5.6.2.1. Biosimilars
      • 5.6.2.2. Generic drugs
    • 5.6.3. COLLABORATIONS AMONG COMPANIES
    • 5.6.4. FOCUS ON OVERCOMING UNMET MEDICAL NEEDS
    • 5.6.5. EMERGING MARKETS
  • 5.7. CHALLENGES
    • 5.7.1. PRODUCT RECALLS
    • 5.7.2. PATENT EXPIRY AND PATENT CLIFF
    • 5.7.3. REGULATORY HURDLES AND PRICING PRESSURE

6. DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. INTRODUCTION
  • 6.2. ORAL DRUG DELIVERY
    • 6.2.1. SOLID ORAL DRUGS
      • 6.2.1.1. Tablets
      • 6.2.1.2. Capsules
      • 6.2.1.3. Powders
      • 6.2.1.4. Pills
    • 6.2.2. LIQUID ORAL DRUGS
      • 6.2.2.1. Solutions
      • 6.2.2.2. Syrups
    • 6.2.3. SEMI-SOLID ORAL DRUGS
      • 6.2.3.1. Gels
      • 6.2.3.2. Emulsions
      • 6.2.3.3. Elixirs
  • 6.3. PULMONARY DRUG DELIVERY
    • 6.3.1. METERED DOSE INHALERS
    • 6.3.2. DRY POWDER INHALERS
    • 6.3.3. NEBULIZERS
      • 6.3.3.1. Jet Nebulizers
      • 6.3.3.2. Ultrasonic Nebulizers
      • 6.3.3.3. Soft Mist Nebulizers
  • 6.4. INJECTABLE DRUG DELIVERY
    • 6.4.1. INJECTABLE DRUG DELIVERY DEVICES
      • 6.4.1.1. Conventional injectables
      • 6.4.1.2. By Material
        • 6.4.1.2.1.1. Glass
        • 6.4.1.2.1.2. Plastic
      • 6.4.1.3. By Product
        • 6.4.1.3.1.1. Fillable Syringes
        • 6.4.1.3.1.2. Prefilled Syringes
      • 6.4.1.4. By Usability
        • 6.4.1.4.1.1. Reusable Syringes
        • 6.4.1.4.1.2. Disposable Syringes
      • 6.4.1.5. Self-injection devices
      • 6.4.1.6. Needle-free Injectors
      • 6.4.1.7. Autoinjectors
      • 6.4.1.8. Pen Injectors
      • 6.4.1.9. Wearable Injectors
      • 6.4.1.10. Other Devices
    • 6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS
      • 6.4.2.1. Conventional Drug Delivery
      • 6.4.2.2. Novel Drug Delivery Formulations
      • 6.4.2.3. Long-acting Injection Formulations
  • 6.5. OCULAR DRUG DELIVERY
    • 6.5.1. LIQUID OCULAR DRUG DELIVERY
      • 6.5.1.1. Eye Drops
      • 6.5.1.2. Liquid Sprays
    • 6.5.2. SEMI-SOLID OCULAR DRUG DELIVERY
      • 6.5.2.1. Gels
      • 6.5.2.2. Eye Ointments
    • 6.5.3. OCULAR DEVICES
      • 6.5.3.1. Contact Lenses Coated with Drugs
      • 6.5.3.2. Ocular Inserts
  • 6.6. NASAL DRUG DELIVERY
    • 6.6.1. NASAL DROPS
    • 6.6.2. NASAL SPRAYS
    • 6.6.3. NASAL POWDERS
    • 6.6.4. NASAL GELS
  • 6.7. TOPICAL DRUG DELIVERY
    • 6.7.1. LIQUID TOPICAL DRUG DELIVERY
      • 6.7.1.1. Solutions
      • 6.7.1.2. Suspensions
    • 6.7.2. SEMI-SOLID TOPICAL DRUG DELIVERY
      • 6.7.2.1. Creams
      • 6.7.2.2. Gels
      • 6.7.2.3. Ointments
      • 6.7.2.4. Pastes
      • 6.7.2.5. Lotions
    • 6.7.3. SOLID TOPICAL DRUG DELIVERY
      • 6.7.3.1. Suppositories
      • 6.7.3.2. Powders
    • 6.7.4. TRANSDERMAL DRUG DELIVERY
      • 6.7.4.1. Transdermal Patches
      • 6.7.4.2. Transdermal Gels
  • 6.8. IMPLANTABLE DRUG DELIVERY
    • 6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY
    • 6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY
  • 6.9. TRANSMUCOSAL DRUG DELIVERY
    • 6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY
      • 6.9.1.1. Buccal Drug Delivery
      • 6.9.1.2. Sublingual drug delivery
    • 6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY
      • 6.9.2.1. Rectal Transmucosal Drug Delivery
      • 6.9.2.2. Vaginal Transmucosal Drug Delivery

7. DRUG DELIVERY TECHNOLOGY MARKET, BY END USER

  • 7.1. INTRODUCTION
  • 7.2. HOSPITALS
  • 7.3. HOME CARE SETTINGS
  • 7.4. AMBULATORY SURGICAL CENTERS/CLINICS
  • 7.5. DIAGNOSTIC CENTERS
  • 7.6. OTHER END USERS

8. DRUG DELIVERY TECHNOLOGY MARKET, BY REGION

  • 8.1. INTRODUCTION
  • 8.2. NORTH AMERICA
    • 8.2.1. U.S.
    • 8.2.2. CANADA
  • 8.3. EUROPE
  • 8.4. ASIA
  • 8.5. REST OF THE WORLD

9. COMPETITIVE LANDSCAPE

  • 9.1. OVERVIEW
  • 9.2. MARKET SHARE ANALYSIS
  • 9.3. COMPETITIVE SITUATIONS & TRENDS
    • 9.3.1. NEW PRODUCT LAUNCHES & APPROVALS
    • 9.3.2. PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
    • 9.3.3. ACQUISITIONS
    • 9.3.4. EXPANSIONS

10. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 10.1. INTRODUCTION
  • 10.2. BAYER AG
  • 10.3. JOHNSON & JOHNSON SERVICES, INC.
  • 10.4. NOVARTIS AG
  • 10.5. PFIZER, INC.
  • 10.6. F. HOFFMANN-LA ROCHE LTD.
  • 10.7. 3M COMPANY
  • 10.8. ANTARES PHARMA, INC.
  • 10.9. GLAXOSMITHKLINE PLC
  • 10.10. MERCK & CO., INC.
  • 10.11. SANOFI

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

11. APPENDIX

  • 11.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 11.2. DISCUSSION GUIDE
  • 11.3. OTHER DEVELOPMENTS, 2012-2015
  • 11.4. AVAILABLE CUSTOMIZATIONS
  • 11.5. RT: REAL-TIME MARKET INTELLIGENCE
  • 11.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: LIST OF BIOLOGICS EXPECTED TO GAIN U.S. REGULATORY APPROVAL IN 2015
  • TABLE 2: MAJOR PRODUCT LAUNCHES IN 2015
  • TABLE 3: EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY (2014-2015)
  • TABLE 4: RISING PREVALENCE OF CHRONIC DISEASES IS DRIVING MARKET GROWTH
  • TABLE 5: RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS RELATED TO DRUGS ARE RESTRAINING MARKET GROWTH
  • TABLE 6: RECENT COLLABORATIONS IN THE DRUG DELIVERY TECHNOLOGY MARKET, 2014-2015
  • TABLE 7: EMERGING MARKETS EXPECTED TO OFFER SIGNIFICANT OPPORTUNITIES FOR MARKET PLAYERS
  • TABLE 8: MAJOR PRODUCT RECALLS IN THE DRUG DELIVERY TECHNOLOGY MARKET, 2015
  • TABLE 9: PATENT EXPIRY OF DRUGS, 2014-2015
  • TABLE 10: PRODUCT RECALLS POSE A SIGNIFICANT CHALLENGE FOR MARKET GROWTH
  • TABLE 11: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013-2020 (USD BILLION)
  • TABLE 12: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 13: ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 14: ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 15: ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLID DRUGS, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 16: ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLID DRUGS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 17: SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR TABLETS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 18: SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR CAPSULES, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 19: SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR POWDERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 20: SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR PILLS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 21: LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 22: LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 23: LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLUTIONS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 24: LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SYRUPS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 25: SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 26: SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 27: SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR GELS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 28: SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR EMULSIONS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 29: SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR ELIXIRS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 30: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 31: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 32: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR METERED DOSE INHALERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 33: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR DRY POWDER INHALERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 34: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR NEBULIZERS, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 35: PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR NEBULIZERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 36: JET NEBULIZERS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 37: ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 38: SOFT MIST NEBULIZERS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 39: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 40: INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 41: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 42: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 43: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 44: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY MATERIAL, 2013-2020 (USD BILLION)
  • TABLE 45: CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 46: CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 47: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY PRODUCT, 2013-2020 (USD BILLION)
  • TABLE 48: CONVENTIONAL FILLABLE SYRINGES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 49: CONVENTIONAL PREFILLED SYRINGES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 50: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY USABILITY, 2013-2020 (USD BILLION)
  • TABLE 51: CONVENTIONAL REUSABLE SYRINGES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 52: CONVENTIONAL DISPOSABLE SYRINGES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 53: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR SELF-INJECTION DEVICES, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 54: INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR SELF-INJECTION DEVICES, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 55: NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 56: AUTOINJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 57: PEN INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 58: WEARABLE INJECTORS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 59: OTHER DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 60: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
  • TABLE 61: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 62: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 63: NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 64: LONG-ACTING INJECTION FORMULATIONS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 65: OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 66: OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 67: LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 68: LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 69: LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR EYE DROPS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 70: LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR LIQUID SPRAYS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 71: SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 72: SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 73: SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR GELS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 74: SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR EYE OINTMENTS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 75: OCULAR DEVICES DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 76: OCULAR DEVICES DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 77: CONTACT LENS COATED WITH DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 78: OCULAR INSERTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 79: NASAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 80: NASAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 81: NASAL DROPS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 82: NASAL SPRAYS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 83: NASAL POWDERS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 84: NASAL GELS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 85: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 86: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 87: LIQUID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 88: LIQUID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 89: TOPICAL DRUG DELIVERY SOLUTIONS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 90: TOPICAL DRUG DELIVERY SUSPENSIONS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 91: SEMI-SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 92: SEMI-SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 93: TOPICAL DRUG DELIVERY CREAMS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 94: TOPICAL DRUG DELIVERY GELS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 95: TOPICAL DRUG DELIVERY OINTMENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 96: TOPICAL DRUG DELIVERY PASTES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 97: TOPICAL DRUG DELIVERY LOTIONS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 98: SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 99: SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 100: TOPICAL DRUG DELIVERY SUPPOSITORIES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 101: TOPICAL DRUG DELIVERY POWDERS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 102: TRANSDERMAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 103: TRANSDERMAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 104: TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 105: TRANSDERMAL GELS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 106: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 107: IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 108: ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 109: PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 110: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 111: TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 112: ORAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 113: ORAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 114: BUCCAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 115: SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 116: OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013-2020 (USD BILLION)
  • TABLE 117: OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 118: RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 119: VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 120: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD BILLION)
  • TABLE 121: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 122: DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR HOSPITALS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 123: DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR HOME CARE SETTINGS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 124: DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR AMBULATORY SURGICAL CENTERS/CLINICS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 125: DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR DIAGNOSTIC CENTERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 126: DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR OTHER END USERS, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 127: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
  • TABLE 128: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
  • TABLE 129: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013-2020 (USD BILLION)
  • TABLE 130: NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD BILLION)
  • TABLE 131: U.S.: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013-2020 (USD BILLION)
  • TABLE 132: U.S.: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD BILLION)
  • TABLE 133: CANADA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013-2020 (USD BILLION)
  • TABLE 134: CANADA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD BILLION)
  • TABLE 135: EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013-2020 (USD BILLION)
  • TABLE 136: EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD BILLION)
  • TABLE 137: ASIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013-2020 (USD BILLION)
  • TABLE 138: ASIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD BILLION)
  • TABLE 139: ROW: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013-2020 (USD BILLION)
  • TABLE 140: ROW: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD BILLION)
  • TABLE 141: NEW PRODUCT LAUNCHES & APPROVALS, 2012-2015
  • TABLE 142: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS, 2012-2015
  • TABLE 143: ACQUISITIONS, 2012-2015
  • TABLE 144: EXPANSIONS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION (2015 VS. 2020)
  • FIGURE 7: ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2015 VS. 2020
  • FIGURE 8: HOSPITALS FORM THE LARGEST END-USER SEGMENT
  • FIGURE 9: TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2015 VS. 2020
  • FIGURE 10: TOPICAL DRUG DELIVERY SEGMENT TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020
  • FIGURE 11: HOSPITALS SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD
  • FIGURE 12: TABLETS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015
  • FIGURE 13: INJECTABLE DRUG DELIVERY TECHNOLOGY TO OFFER SIGNIFICANT CONTRIBUTION TO THE OVERALL MARKET GROWTH (2015-2020)
  • FIGURE 14: ASIA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 15: DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
  • FIGURE 16: DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY END USER
  • FIGURE 17: DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY REGION
  • FIGURE 18: DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19: TOPICAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 20: SOLID ORAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 21: NEBULIZERS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 22: FORMULATIONS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 23: LIQUID OCULAR DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 24: NASAL SPRAYS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 25: SEMI-SOLID TOPICAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 26: PASSIVE IMPLANTABLE DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 27: ORAL TRANSMUCOSAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 28: DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY END USER
  • FIGURE 29: DRUG DELIVERY TECHNOLOGY MARKET, BY END USER: HOSPITALS TO HOLD LARGEST MARKET SHARE IN 2015
  • FIGURE 30: NORTH AMERICA TO HOLD THE LARGEST SHARE OF THE GLOBAL DRUG DELIVERY TECHNOLOGY MARKET (2015)
  • FIGURE 31: EUROPEAN DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT (2015)
  • FIGURE 32: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE GLOBAL DRUG DELIVERY TECHNOLOGY MARKET (2015)
  • FIGURE 33: RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET IN THE ROW (2015)
  • FIGURE 34: NEW PRODUCT LAUNCHES & APPROVALS IS THE KEY GROWTH STRATEGY ADOPTED BY PLAYERS IN THE DRUG DELIVERY MARKET DURING THE STUDIED PERIOD (2014-2015)
  • FIGURE 35: GLOBAL DRUG DELIVERY TECHNOLOGY MARKET SHARE, BY KEY PLAYER (2014)
  • FIGURE 36: MARKET EVOLUTION FRAMEWORK: NEW PRODUCT LAUNCHES & APPROVALS ARE FUELING MARKET GROWTH
  • FIGURE 37: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES & APPROVALS IS THE KEY GROWTH STRATEGY ADOPTED BY LEADING PLAYERS IN 2015
  • FIGURE 38: GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS
  • FIGURE 39: BAYER AG: COMPANY SNAPSHOT
  • FIGURE 40: JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • FIGURE 41: NOVARTIS AG: COMPANY SNAPSHOT
  • FIGURE 42: PFIZER, INC.: COMPANY SNAPSHOT
  • FIGURE 43: F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • FIGURE 44: 3M COMPANY: COMPANY SNAPSHOT
  • FIGURE 45: ANTARES PHARMA, INC: COMPANY SNAPSHOT
  • FIGURE 46: GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • FIGURE 47: MERCK & CO., INC.: COMPANY SNAPSHOT
  • FIGURE 48: SANOFI: COMPANY SNAPSHOT
Back to Top